May 14, 2019
Haemonetics To Transfer Union, South Carolina, Manufacturing Facility To CSL Plasma Inc.
Apr 25, 2019
CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]
Mar 29, 2019
Global Antidiuretic Drugs Market 2019-2023 with Avadel, CSL Limited, Ferring B.V., Novartis & Sanofi Dominating
Feb 04, 2019
CSL Behring Extends Support of World Federation of Hemophilia Programs
Dec 06, 2018
CSL CEO Paul Perreault Earns 2018 Most Admired CEOs Recognition from the Philadelphia Business Journal
Nov 21, 2018
Albumin Market to Reach $10.31 Bn, Globally, by 2023 at 9.6% CAGR, Says Allied Market Research
Nov 16, 2018
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
Nov 16, 2018
Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options
Oct 23, 2018
Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
Sep 18, 2018
CSL Named One of the Top Companies in the World for Diversity and Inclusion
Aug 23, 2018
Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process
Aug 22, 2018
Vaccines Market to Grow at 6.7% CAGR and to Reach US$ 50.42 Billion by 2023, Led by Hepatitis and Influenza
Aug 08, 2018
Seqirus Begins Shipping 2018-2019 Influenza Vaccines to the U.S. Market
Jul 20, 2018
CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting
Jul 04, 2018
Intravenous Immunoglobulin (IVIg): World Strategic Business Outlook 2018-2024 - Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
Jun 22, 2018
A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant
May 31, 2018
IDELVION® Newly Approved 3500 IU Vial to Provide Convenience to Patients Using Larger Volumes
May 14, 2018
Hemophilia Association Of New Jersey Recognizes CSL CEO Paul Perreault As "Humanitarian Man Of The Year"
Apr 26, 2018
Patient Advocacy Groups Focus On Key Issues Affecting Patients
Apr 20, 2018
CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting